<DOC>
	<DOCNO>NCT01293773</DOCNO>
	<brief_summary>Design : prospective , randomize , multi-center trial compare safety efficacy prevention target lesion failure ( TLF ) second generation paclitaxel- versus ABT578- versus Everolimus- eluting stent Study Population : consecutive diabetic patient de novo coronary artery lesion undergo drug-eluting stent implantation 2010-12 . Time Course : initial Enrollment : October 2010 ; end Enrollment : December 2012 Primary End-Point : target lesion revascularization ( TLF ) define occurrence cardiac death , myocardial infarction repeat lesion revascularization within 12 month . Secondary End-Points : 1 ) impact glucose level first three month follow procedure ( assessed hemoglobin A1C ) clinically-driven target lesion revascularization ; 2 ) TLF TLR within 12 , 24 36 month ; 3 ) comparison 12 month versus prolong ( &gt; 12 month ) dual antiplatelet therapy</brief_summary>
	<brief_title>Outcome Second Generation Drug-eLuting Stents Patients With Diabetes Mellitus</brief_title>
	<detailed_description>Prospective , randomize , triple arm study . The study population include consecutive diabetic patient within 24 month undergoing elective second generation DES implantation de novo coronary artery disease . In randomization process participate center equally stratify avoid statistical unbalance .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>1 . Subject &gt; 18 year old 2 . Presence one de novo stenosis equal great 70 % native coronary artery , treat second generation drugeluting stent 3 . Subject treat physician agree subject comply followup evaluation 4 . Subject informed nature study agree provision provide write informed consent approve Institutional Review Board/Ethics Committee respective clinical site 1 . Subject 's age &lt; 18 year acute myocardial infarction 48 prior procedure 2 . The patient pregnant breastfeeding 3 . Known allergy : aspirin , clopidogrel ( Plavix ) ticlopidine ( tiklid ) , heparin , Paclitaxel , Everolimus , ABT 578 , stainless steel , contrast agent ( adequately premedicated ) 4 . A platelet count &lt; 75,000 cells/mm3 &gt; 700,000 cells/mm3 WBC &lt; 3,000 cells/mm3 5 . Subject currently participate investigational drug device study complete primary endpoint clinically interfere current study endpoint 6 . Prior participation study 7 . Active peptic ulcer upper GI bleeding within prior 3 month 8 . Subject active sepsis 9 . Any lesion locate saphenous vein graft 10 . In investigator 's opinion , subject comorbid condition ( ) could limit life expectancy le one year , limit subject 's ability participate study comply followup requirement impact scientific integrity study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Randomized control trial</keyword>
	<keyword>Drug-eluting Stent</keyword>
	<keyword>Multicenter study</keyword>
</DOC>